Understanding Polypoidal choroidal vasculopathy
PCV includes a branching abnormal vessel network with focal polypoidal or aneurysmal lesions, commonly beneath the retinal pigment epithelium. It is often discussed within the neovascular AMD spectrum, but nomenclature and its relationship to other choroidal patterns remain debated. A PCV diagnosis is more specific than simply saying wet macular disease. [2] [5]
Some lesions are found before noticeable symptoms; active leakage, hemorrhage, scarring or tissue loss can affect vision. PCV occurs across populations, with differing frequencies between settings. Ethnicity or age alone cannot establish or exclude the diagnosis. [1] [2]
One condition. Different experiences.
Explore different selected symptom features, then read how they may vary. These examples are not stages or a clinical test.
Original VisualSim schematic illustrations, informed by the cited clinical descriptions. These are not study figures, patient recordings or validated severity levels.
Central blur
Reading and recognition may become less clear in one or both eyes. The effect depends on lesion location and activity, so a mildly affected or inactive eye may not resemble a dramatic illustration. [1] [5]
Distortion or a missing area
Fluid, blood or damaged central tissue can produce bent lines or a patch of reduced detail. The appearance does not tell whether a polypoidal lesion is open, closed or actively leaking. [1] [2]
A sudden change after stability
Bleeding can cause a rapid deterioration even after a relatively stable period. New symptoms warrant review rather than automatically assuming gradual age-related change. [1] [5]
Anatomy, activity and function
Original conceptual schematic; no universal sequence or individual treatment response is implied. [1] [2] [5]
Original VisualSim teaching diagram · © VisualSim. Clinical basis in linked sources; not a published study figure. Image provenance.- Vascular pattern
A branching network and focal lesions develop beneath retinal layers.
- Activity
Leakage or bleeding can disturb the overlying central retina.
- Follow-up
Vision, fluid and lesion activity can respond differently.
What is happening—and what remains uncertain
The abnormal vascular network and focal lesions can leak fluid or blood into or beneath retinal layers. This can disrupt photoreceptors and, over time, leave scar or atrophy. An orange lesion in an examination image is not necessarily an orange object in the person’s view. [1] [5]
Anti-VEGF treatment suppresses a pathway involved in leakage, while verteporfin photodynamic therapy targets the abnormal vascular lesion through a photosensitizing drug and directed light. Their effects on fluid, lesion closure and visual function are related but not identical outcomes. [1] [3] [4]
What can look similar?
Other neovascular AMD
PCV shares features and treatments with other neovascular macular disease, but a particular vascular pattern can affect treatment planning. A suboptimal response to one injection course is a reason to reassess the diagnosis and activity, not proof of PCV by itself. [2] [5]
Similar-looking symptoms can have different causes. A matching picture cannot establish a diagnosis.
What an assessment may involve
- Dilated examination and OCTThe specialist assesses both eyes and uses OCT to examine fluid, pigment-epithelium elevations and other structural clues. An OCT pattern helps guide diagnosis but requires clinical interpretation. [1] [2]
- Vascular imagingIndocyanine-green angiography can identify polypoidal lesions and the network, especially when the diagnosis is uncertain. OCT and OCT angiography provide useful noninvasive features in selected settings; access and the specific question influence the imaging plan. [1] [2]
- Track distinct outcomesAsk whether follow-up measures visual function, fluid control, hemorrhage and lesion activity separately. A dry scan or regressed lesion does not guarantee restoration of damaged retinal tissue or eliminate future recurrence. [2] [5]
What may help—and what is still being studied
Anti-VEGF treatment
Injections are a main treatment for active macular PCV. Drug choice, interval and retreatment depend on the actual response and local access. Studies of one agent or regimen cannot establish the best interval for every other medicine. [2] [3] [4]
Photodynamic therapy as a specific option
PDT may be combined with injections or considered in selected persistent or recurrent disease. Discuss available evidence, verteporfin access and risks. After PDT, follow the team’s precise light-exposure precautions; ordinary sunglasses are not a substitute for the full instructions. [1] [2] [5]
What this can mean for daily life
Keep treatment accessible
Record eye, drug and appointment dates, with a contact for missed visits or a sudden change. Ask about transport and support if repeated injections create financial, work or caring pressures. [5] [7]
Use adaptable reading tools
Magnification, reflowing text, audio and suitable contrast can support central tasks. The most useful setup is one you can sustain, not the highest magnification available. [7]
Make symptom reports concrete
Describe the start and location of distortion and a task it affects. Follow a clinic-provided monitoring plan without treating a home grid or simulation as a measurement of vessel activity. [1] [5]
Connect to macular support
Broader macular charities can provide practical and emotional help even without a PCV-only local group. Peer accounts may involve a different drug or imaging pattern and cannot decide whether you need PDT. [7]
Bring a clearer description to your appointment
Choose the questions you want to discuss. These choices stay in this page’s memory.
Research, with the context left in
Selected studies and guidance, with their populations and limitations. These are curated educational summaries, not a complete systematic review or a formal evidence rating.
EVEREST II: prompt PDT plus ranibizumab
Prompt combination therapy improved mean acuity and lesion regression and reduced injection burden compared with the specified ranibizumab-alone strategy. [3]
Limits and applicability: Results concern this agent, timing and population; they do not prove that adding PDT is superior to every other anti-VEGF regimen or for inactive lesions.
PLANET: aflibercept with possible rescue PDT
Aflibercept without active rescue PDT was noninferior on acuity to the rescue-PDT strategy, and most participants never met rescue criteria. [4]
Limits and applicability: Because few received rescue PDT, the study cannot determine the benefit of routinely adding prompt PDT. It tested a different question from EVEREST II.
APVRS consensus and guidelines
Supports multimodal diagnosis and individualized strategies that account for activity and evolving treatment evidence. [2]
Limits and applicability: Expert agreement is not a comparative trial or proof of one universally best protocol. Longer-term outcomes and access remain unsettled.
Questions researchers still need to answer
- Which patients gain meaningful added benefit from prompt versus rescue PDT with newer injection regimens?
- What predicts recurrence, atrophy and long-term reading ability beyond early fluid control?
Trusted places to go next
Selected clinical references, research, practical support and ways to connect. Official pages checked 24 October 2026; each entry explains its scope and region.
ASRS — polypoidal choroidal vasculopathy
Focused patient explanation and retinal-specialist education; treatment intervals require an individual plan.
Singapore National Eye Centre — Retina Centre
A real medical-retina service explicitly treating PCV, with imaging and rehabilitation pathways and visit guides in four languages. Referral, fees and eligibility require local confirmation.
Macular Society
Advice, counseling and peer support for central-vision difficulties; not a PCV-specific treatment authority.
Connections listed by the organization.
Macular Disease Foundation Australia
Macular-disease support navigation and practical information for affected people and families.
Connections listed by the organization.
Questions you may still have
Are polyps in the eye the same as a tumor?
No. The term here describes focal abnormal vascular lesions; it does not mean a bowel-type polyp or establish cancer. Retinal imaging identifies the actual anatomy. [2] [5]
Does everyone need PDT immediately?
No. Trials differ in drug, timing and rescue rules. The specialist balances activity, response, evidence and access rather than applying one combination to everyone. [2] [3] [4]
Does a closed lesion mean the eye is cured?
No. Lesion regression, fluid control and useful vision are different outcomes, and recurrence remains possible. Continue the agreed follow-up. [5]
Can PCV be present before I notice it?
Yes. Some lesions are detected without symptoms. Conversely, a new visual change still needs examination even when an earlier scan was stable. [1]
Sources, image credits and review status
Compiled by VisualSim from clinical references and published research. Sources checked 24 October 2026. Independent clinical review has not been recorded; no named clinical reviewer or clinical validation is claimed. Research evidence and its limitations are linked below.
- ASRS — Polypoidal Choroidal Vasculopathy (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - APVRS — Consensus and guidelines on PCV diagnosis and management (2025; guideline).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Lim et al. — EVEREST II 24-month randomized trial (2020; trial).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Lee et al. — PLANET randomized clinical trial (2018; trial).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Koh et al. — Long-Term Management of PCV: A Narrative Review (2026; review).
Current April 2026 review, long-term limitations and funding/conflicts checked. Narrative synthesis, including industry author and sponsor review; original trials prioritized for comparisons.
Checked 2026-10-24 · Full text checked - Singapore National Eye Centre — Retina Centre (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - Macular Society — support and practical information (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - NHS — Vision loss (n.d.; institution).
Official sudden sight-loss/severe pain emergency versus other urgent visual-change guidance checked; local service routes vary internationally.
Checked 2026-10-24 · Public page checked
The simulator helps people communicate an experience. It cannot diagnose a condition, measure a visual field, or establish that someone is safe to drive.